$30 Billion Hepatitis C Market: Drug Development Pipeline Study, H2 2018 - ResearchAndMarkets.com
Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.adaptimmune.com/phoenix.zhtml?c=253991&p=irol-newsarticle&id=2255800
Company Research
Source: Business Wire
DUBLIN--(BUSINESS WIRE)-- The "Hepatitis C: Drug Development Pipeline Study, H2 2018" report has been added to ResearchAndMarkets.com's offering. With an estimated market value of over $30 billion by 2020, the Hepatitis C industry is considered as a rapidly growing healthcare market. Hepatitis C pipeline comprises of 85 active drugs under active development as of June 2018. Of these, 16 drugs are in Phase 1 and 19 drugs in phase 2. Only 4 drugs progressed to Phase 3. Further, 27 drugs are in Pre-clinical stage, 18 drugs in research/discovery stages. 60 companies are developing the pipeline for Hepatitis C. Of this, GinkgoPharma Co. Ltd, Biocad CJSC, Cocrystal Pharma Inc, ARA Healthcare Pvt Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Beijing Kawin Technology Share-Holding Co., Ltd. and Achillion Pharmaceuticals, Inc. have more compounds in the pipeline. On the other hand, Presidio Pharm
Show less
Read more
Impact Snapshot
Event Time:
ADAP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAP alerts
High impacting Adaptimmune Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ADAP
News
- Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024 [Yahoo! Finance]Yahoo! Finance
- Global CD70 Targeting Therapies Market & Clinical Trials Report 2024 - Insight by Company, Country, Indication & Phase [Yahoo! Finance]Yahoo! Finance
- Adaptimmune: Huge Opportunity Amid Their Setback With Genentech [Seeking Alpha]Seeking Alpha
- Garry Menzel joins GHO Capital as Operating Partner [Yahoo! Finance]Yahoo! Finance
- Adaptimmune (ADAP) Down on End of Collaboration With Roche [Yahoo! Finance]Yahoo! Finance
ADAP
Sec Filings
- 4/22/24 - Form ARS
- 4/12/24 - Form 8-K
- 4/11/24 - Form DEF
- ADAP's page on the SEC website